In a phase 3 trial published Oct. 25, 2026, in NEJM, people with PD-L1-negative advanced lung cancer went a median 15.0 months without progression on sacituzumab tirumotecan plus pembrolizumab vs. 5.7 months…
In a phase 3 trial published Oct. 26, 2026, in The Lancet, people with EGFR lung cancer that grew on EGFR pills went a median 8.3 months without progression on ruzaltatug rezetecan,…
In the NeoCOAST-2 trial, published Oct. 25, 2026, in Nature, people with operable lung cancer whose tumor DNA disappeared from the blood during treatment before surgery had much longer event-free survival (hazard…
In the phase 2 MDT-BRIDGE trial, published Oct. 26, 2026, in Nature Medicine, 142 people with resectable or borderline lung cancer got durvalumab plus chemotherapy before surgery; 74.6% had their tumor removed…
In a phase 3 trial published Oct. 25, 2026, in the New England Journal of Medicine, divarasib, a new KRAS G12C pill, extended median survival to 17.7 months vs. 12.0 months with…
In a phase 3 trial published Oct. 26, 2026, in the Journal of Clinical Oncology, people with EGFR lung cancer that escaped EGFR pills through MET amplification went a median 6.2 months…
